Unreliable data: how a tiny US company influenced Covid-19 policy globally
In May a single study published in one of the world's leading medical journals led to trials of a possible coronavirus treatment being halted around the world. Weeks later the study was retracted and the company behind the data used is facing serious scrutiny. Melissa Davey tells us how it all unravelled
You can read Melissa Davey's feature on how unreliable data in Covid-19 research was questioned
The Guardian is editorially independent.
And we want to keep our journalism open and accessible to all.
But we increasingly need our readers to fund our work.